Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : Breaks Ground on its First Zero Energy Building in Singapore

09/22/2021 | 10:12pm EDT

Singapore, September 23, 2021 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") announced today the official groundbreaking of its first building to follow the Singapore Green Mark Zero Energy certification scheme within the company's global manufacturing and supply network in Woodlands, Singapore. The building, a $14 million USD expansion of Takeda's manufacturing operations in Singapore, is the first 'net zero carbon emissions' building in its global network and a first-of-its-kind investment within the biotechnology industry in Singapore.

A delegation of Takeda's global executive team welcomed the attendance of Mr. Gan Kim Yong, Singapore's Minister for Trade and Industry (MTI), His Excellency Jun Yamazaki, the Japanese Ambassador to Singapore, Mr. Tan Kong Hwee, Executive Vice President of the Singapore Economic Development Board (EDB), Mr. Alvin Tan, Assistant CEO of Industry Cluster Group of JTC, and other partners and guests to the groundbreaking ceremony.

"The groundbreaking of our first zero energy building demonstrates Takeda's commitment to deliver on our environmental goals," said Thomas Wozniewski, global manufacturing and supply officer of Takeda. "Takeda achieved carbon neutrality in 2020, now we are focused on our next step to become net zero by 2040. We are honored to have the opportunity to work with our partners in the region and to support the Singapore government's efforts in tackling climate change."

"Singapore is an important hub for Takeda. In addition to serving as our regional headquarters, our Asia Pacific Area Office is also based here. We are excited to celebrate this momentous groundbreaking event, as this milestone is a remarkable testimonial to the strides Singapore has made to ensure a safe and sustainable environment for our employees, patients and partners," said Ricardo Marek, president, Growth and Emerging Markets Business Unit, Takeda. "Singapore will continue to play an essential role in our objective to increase patient access to Takeda's life-changing treatments across the region, and to promote sustainable growth of our business and people, all while helping to play a role in safeguarding our planet."

Located next to Takeda's biologics manufacturing plant in JTC's Woodlands Wafer Fab Park, Takeda's new zero energy building is planned for occupancy by 2022. The building follows standards from the Singapore Building Construction Authority's (BCA) Green Mark (GM) certification scheme and sets the bar for green energy design. The GM scheme is an internationally recognized green building rating tool tailored for the tropical climate to evaluate a building's environmental impact and performance throughout its lifecycle, and is aligned with the United Nations' Sustainable Development Goals. The approval processes includes the design, piling, construction, occupation and completion phases. The 60-hectare Woodlands Wafer Fab Park caters to the stringent operating requirements of global semiconductor and biomedical firms.

"Takeda's new zero emissions building in Woodlands Wafer Fab Park is an environmentally sustainable advanced manufacturing support facility that complements our efforts in greening Singapore's industrial estates," said Mr. Cheong Wee Lee, director, Biomedical and Electronics Cluster, JTC. "Such close partnerships with companies are critical to our success in reducing Singapore's carbon footprint and creating a conducive work environment."

To achieve the zero energy building status, comprehensive energy studies were conducted to consider Singapore's tropical, very hot and humid equatorial climate. The project includes over 660 solar photo voltaic (PV) panels to fully offset the building's energy consumption, CO2 sensors to regulate fresh air demand, a hybrid AC system with assistance of ceiling fans and thermal diffusers to optimize energy usage and improve air circulation and air flow to ensure user well-being. Additionally, the building also utilizes rainwater harvesting and the use of green concrete.

As a science-based company, Takeda is committed to preserving and protecting the health of the planet. This groundbreaking is an important step in Takeda's sustainability efforts, rooted in the company's purpose of creating better health for patients and a brighter future for the world. To learn more about Takeda's commitment to the planet, please visit: https://www.takeda.com/corporate-responsibility/environment/

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Media Contacts:

Media in Singapore

Vince Docherty
+65 8332-4233

Wendy Chung
+65 8321-5611

Japanese Media

Ryoko Matsumoto
+81 (0) 3-3278-3414

Media Outside Japan and Singapore

Christina Beckerman
+1 781-482-0831

Important Notice

For the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.


Takeda Pharmaceutical Co. Ltd. published this content on 23 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2021 02:11:06 UTC.

© Publicnow 2021
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
10/18CALITHERA BIOSCIENCES : Buys Two Clinical-Stage Assets from Takeda to Boost Oncology Pipel..
10/18Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
10/13TR1 : Notification of Major Shareholding
10/13TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Expansion of Plasma Donation Cen..
10/13Immusoft and Takeda Pharmaceutical Company Limited Collaborate to Discover and Develop ..
10/12POSEIDA THERAPEUTICS : Takeda to Jointly Develop Novel Non-Viral In Vivo Gene Therapies
10/12Poseida Therapeutics, Inc. Announces Research Collaboration with Takeda Pharmaceutical ..
10/12Poseida Therapeutics, Takeda Pharmaceutical in Research, License Pact
More news
More recommendations
Sales 2022 3 391 B 29 661 M 29 661 M
Net income 2022 248 B 2 169 M 2 169 M
Net Debt 2022 3 258 B 28 497 M 28 497 M
P/E ratio 2022 20,5x
Yield 2022 5,61%
Capitalization 5 024 B 43 976 M 43 952 M
EV / Sales 2022 2,44x
EV / Sales 2023 2,30x
Nbr of Employees 47 099
Free-Float 99,3%
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 207,00 JPY
Average target price 4 487,14 JPY
Spread / Average Target 39,9%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.74%421 513
ROCHE HOLDING AG17.78%342 644
NOVO NORDISK A/S56.38%238 110
PFIZER, INC.12.71%231 668